Latest Articles

Publication Date
All News Scientific
Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD - Contemporary OB/GYN

Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD Contemporary OB/GYN

Published: July 15, 2026, 5:16 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
AI for employee burnout: How leaders can help, not harm - Caledonian Record

AI for employee burnout: How leaders can help, not harm Caledonian Record

Published: July 15, 2026, 3:01 p.m.
Read Full Article
Stem cell science unlocks more mysteries of the menstrual cycle - Medical Xpress

Stem cell science unlocks more mysteries of the menstrual cycle Medical Xpress

Published: July 15, 2026, 2 p.m.
Read Full Article
New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset - Femtech Insider

New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset Femtech Insider

Published: July 15, 2026, 12:41 p.m.
Read Full Article
Merck's KEYTRUDA trial may offer a chemo-free option in endometrial cancer - Stock Titan

Merck's KEYTRUDA trial may offer a chemo-free option in endometrial cancer Stock Titan

Published: July 15, 2026, 10:48 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
The harshness of holding back: Pem on creating art through chronic illness - Far Out Magazine

The harshness of holding back: Pem on creating art through chronic illness Far Out Magazine

Published: July 15, 2026, 6 a.m.
Read Full Article
Meta’s $200 Billion Bet On A Remote Data Center Endometriosis (yYBZ7ujXvJ) - Mshale

Meta’s $200 Billion Bet On A Remote Data Center Endometriosis (yYBZ7ujXvJ) Mshale

Published: July 15, 2026, 5:53 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!